Aravive to Participate in Upcoming Virtual Investor Conferences in March
02. März 2021 07:00 ET
|
Aravive, Inc.
HOUSTON, March 02, 2021 (GLOBE NEWSWIRE) -- Aravive, Inc. (Nasdaq: ARAV), a clinical-stage oncology company developing transformative therapeutics, today announced that the Company will present and...
Aravive Announces $21.0 Million Registered Direct Offering with Eshelman Ventures, LLC Priced At-The-Market
16. Februar 2021 07:00 ET
|
Aravive, Inc.
HOUSTON, Feb. 16, 2021 (GLOBE NEWSWIRE) -- Aravive, Inc. (Nasdaq: ARAV), a clinical-stage oncology company developing transformative therapeutics, today announced that it has entered into a...
Aravive to Present at the H.C. Wainwright Virtual BioConnect Conference
04. Januar 2021 16:05 ET
|
Aravive, Inc.
HOUSTON, Jan. 04, 2021 (GLOBE NEWSWIRE) -- Aravive, Inc. (Nasdaq: ARAV), a clinical-stage oncology company developing transformative therapeutics, today announced the Company will present at the...
Aravive Announces Board Member Transition to Advisory Role
31. Dezember 2020 19:00 ET
|
Aravive, Inc.
HOUSTON, Dec. 31, 2020 (GLOBE NEWSWIRE) -- Aravive, Inc. (Nasdaq: ARAV), a clinical-stage oncology company developing transformative therapeutics, today announced that Dr. Ray Tabibiazar will be...
Aravive Announces Phase 3 Trial Design for AVB-500 in Platinum Resistant Ovarian Cancer
19. November 2020 07:00 ET
|
Aravive, Inc.
HOUSTON, Nov. 19, 2020 (GLOBE NEWSWIRE) -- Aravive, Inc. (Nasdaq: ARAV), a clinical-stage oncology company developing transformative therapeutics, today announced the Company has received guidance...
Aravive to Present at the Piper Sandler 32nd Annual Virtual Healthcare Conference
16. November 2020 16:05 ET
|
Aravive, Inc.
HOUSTON, Nov. 16, 2020 (GLOBE NEWSWIRE) -- Aravive, Inc. (Nasdaq: ARAV), a clinical-stage oncology company developing transformative therapeutics, today announced the Company will present and...
Aravive to Host Virtual Expert Event Focused on Ovarian and Renal Cancer on November 20, 2020
10. November 2020 16:05 ET
|
Aravive, Inc.
HOUSTON, Nov. 10, 2020 (GLOBE NEWSWIRE) -- Aravive, Inc. (Nasdaq: ARAV), a clinical-stage oncology company developing transformative therapeutics, today announced the Company will host a virtual...
Aravive and 3D Medicines Announce Strategic Collaboration to Develop and Commercialize AVB-500 in Greater China
10. November 2020 07:00 ET
|
Aravive, Inc.
Aravive to Receive $12 Million Signing Payment, up to an Additional $207 Million in Future Milestone Payments plus Tiered Royalties 3D Medicines to Lead Clinical Development and Commercialization of...
Aravive Reports Third Quarter 2020 Financial Results and Provides Corporate Updates
05. November 2020 16:05 ET
|
Aravive, Inc.
Company expects to initiate pivotal trial of AVB-500 in Platinum Resistant Ovarian Cancer during fourth quarter 2020/first quarter 2021, based on Phase 1b resultsOn-track to initiate Phase 1b/2 trial...
Aravive Appoints Michael W. Rogers to Board of Directors
17. September 2020 07:00 ET
|
Aravive, Inc.
HOUSTON, Sept. 17, 2020 (GLOBE NEWSWIRE) -- Aravive, Inc. (Nasdaq: ARAV), a clinical-stage biopharmaceutical company developing transformative therapeutics, today announced that Michael W. Rogers...